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BACKGROUND The use of drug-eluting balloons (DEB) for the treat-
ment of in-stent restenosis (ISR) and lesions in small vessels has not
been extensively investigated in the real-life clinical practice. Ac-
cording to the most recent guidelines, the use of DEB is indicated only
for the treatment of ISR. We aim to report a three-centers “all comers”
registry on the safety and efﬁcacy of DEB in the treatment of ISR and
de novo coronary artery disease.
METHODS Consecutive patients treated with the In.Pact Falcon
(Medtronic Inc., Minneapolis, MN, USA) paclitaxel-eluting balloon
between January 2012 and November 2014 in the centers of Verona,
Mirano and Savona were retrospectively analyzed in our registry. The
measured clinical end-points were cardiac death, myocardial infarc-
tion (MI), target lesion revascularization (TLR), target vessel revas-
cularization (TVR), while procedural success was deﬁned as the ability
to reach, cross and dilate a lesion with the study device, with a re-
sidual stenosis <30% and a ﬁnal TIMI 3 ﬂow in the culprit vessel.
Primary end point of the study was the occurrence of major adverse
cardiac events (MACE), deﬁned as combination of cardiac death, MI,
and TLR, at 12 and 24 months of follow up.
RESULTS A total of 167 lesions were successfully treated in 143 pa-
tients. The mean age was 67 10 years, and 82.5% were males. The
main risk factors were represented by hypertension and dyslipidemia
while 39.4% of patients were diabetics. The 73.5% of the population
had a prior PCI and the main indication for PCI was because of ACS
(73.5% while 26.5% of patients suffered from stable angina). The
predominant indication for DEB use was ISR (75%), mainly focal
(34.1%), involving a DES in the 79% of cases. Procedural success was
achieved in 97.6%. A mean of 1.10.18 DEB were used per patient.
Bailout stenting was required in 2 lesions. No events were recorded
during the hospitalization. Long term follow up was available for
100% of the study population. The overall incidence of MACEs at 12
months was 5.6%, while at 24 months was 9.1%, with an overall event
free survival of 85%. Of interest, the primary endpoint occurred in
18% of patients treated for de novo lesions, against a 5.7% of ISR pa-
tients (p¼0.01). Patients presenting with focal restenosis had anincidence of events comparable to those with more aggressive rest-
enotic pattern (diffuse or proliferative, p¼0.71).
CONCLUSIONS Our results conﬁrm the safety and efﬁcacy at short
and long term follow up of DEBs, especially in patients presenting
with ISR. On the contrary, the use of DEB in de novo lesions is asso-
ciated with a poorer clinical outcome. Larger trials are needed to
conﬁrm our data.
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BACKGROUND drug-coated balloons (DCB) have shown to be a valu-
able alternative to stents for the treatment of in-stent restenosis, and
there is some initial evidence of their efﬁcacy for the treatment of
small coronary vessels. Newer generation DCB were developed to
overcome the reduced deliverability of the previous generation of
devices, warranting an effective drug delivery to the vessel wall.
However, the vast majority of such devices still lack of reliability due
to paucity of clinical data.
METHODS between 2012-2014 all patients intended to be treated with
this type of DCB at 9 italian centers were enrolled in this retrospective
registry. We did not have speciﬁc exclusion criteria. Coronary in-
terventions were performed following the Italian Position paper on DCB-
PCI published in 2014. Primary outcome was the occurrence of target
lesion revascularization (TLR) at the longest available follow up.
RESULTS we enrolled 247 consecutive patients/283 lesions, whose
clinical, angiographic and procedural characteristics are depicted in
Table. At the longest available clinical follow up (average 225 days,
I.Q. ranges 67 days), 5 patients suffered a TLR, all but one managed
with re-PCI (2 with another type of DCB, 2 with DES). We registered
2 cases of cardiac death (one for heart failure and one for fatal
myocardial infarction related to another vessel), 4 non-cardiac
deaths (2 malignancies and 2 intracranial hemorrhages) and no cases
of target vessel myocardial infarction/thrombosis.
